...

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES

【24h】

HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES

机译：在美国进行一线（1L）系统治疗的转移性肾细胞癌（MRCC）患者的健康资源利用（HRU）和费用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2016年第7期|共1页
作者
Mhatre S.; Lin S.; Surinach A.; Vohra R.; Satram-Hoang S.; Simpson J.; Wallen H.; Ogale S.; Gong J.; Pal S. K.; George D. J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. 索拉非尼与舒尼替尼一线治疗中国转移性肾细胞癌患者的疗效、安全性和生活质量的比较 [J] . Wen Cai, Wen Kong, Baijun Dong, 癌症（英文版） . 2018,第003期
2. HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES [J] . Mhatre S., Lin S., Surinach A., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：在美国进行一线（1L）系统治疗的转移性肾细胞癌（MRCC）患者的健康资源利用（HRU）和费用
3. Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax (VEN) or Chemotherapy (CT)/Chemoimmunotherapy (CIT) [J] . Nabhan Chadi, Mato Anthony R., Kish Jonathan K., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：慢性淋巴细胞白血病（CLL）患者的成本和医疗资源利用（HRU）对疗效（VEN）或化疗（CT）/化疗（CIT）的患者的比较
4. Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy? [J] . Amishi Y. Shah, Jose A. Karam, Zita D. Lim, Urology Case Reports . 2015,第2期

机译：舒尼替尼治疗转移性肾细胞癌（mRCC）患者的临床和病理学完全缓解：靶向治疗可治愈mRCC吗？
5. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
6. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
7. Clinical Outcomes Costs and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy [O] . Ying Zheng, Ting Yu, Rachel H Mackey, 2021

机译：用免疫检查点抑制剂治疗的术语结果成本和医疗保健资源利用患者用免疫检查点抑制剂对化疗进行化学疗法
8. PCN16 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE BEVACIZUMAB (BEV) + LOWER-DOSE INTERFERON-ALPHA2A IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, AND UNITED KINGDOM [O] . Mickisch GH, Escudier B, Gore M, 2009

机译：PCN16在德国，法国和英国对患有转移性肾细胞癌（MRCC）的患者进行第一线贝伐单抗（BEV）+低剂量干扰素-α2A副作用治疗的费用

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号